1.59
+2.58%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Abionyx Pharma
Its shares trade on Euronext Paris under the ticker ABNX.PA. It has been listed since 30 March 2015. In the fiscal year to 31 December 2025, it reported revenue of €4.1m and a net loss of €5.5m. At that date it held total assets of €12.9m and shareholders' equity of €4.3m.
ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. The company is headquartered in Balma, Occitanie. The company went IPO on 2015-03-30. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The firm is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Mar 2015
- Employees
- 14
- Website
- cerenis.com ↗
Leadership
Pay as last reported
- Mr. Emmanuel HuynhChairman of the Board, since 2019€21,000
- Mr. Cyrille TupinChief Executive Officer, Executive Director€288,278
- Mr. Emmanuel De FougerouxChief Financial & Administrative Officer, since 2024
- Ms. Constance KeyserlingSenior Vice President - Clinical Development, since 2024
- Mr. Yann QuentricDeputy General Director - Ophthalmology
- Mr. Ronald BarbarasDirector - Exploratory Biology
- Ms. Renee BenghoziDirector - Clinical Research
- Mr. Laurent GuerciChief Digital & Innovation Officer
- Mr. Jerome MartinezSenior Advisor - Ophthalmology
- Dr. Robert ScottChief Medical Officer, Head - R&D
- Mr. Luc DemarreDirector
- Ms. Caroline DesurmontDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Abionyx Pharma SA has several strengths that contribute to its success in the pharmaceutical industry. Firstly, the company has a strong portfolio of innovative drug candidates, which gives it a competitive edge in the market. These drug candidates are developed using cutting-edge scientific research and technology, ensuring their effectiveness and potential for commercial success. Secondly, Abionyx Pharma SA has a highly skilled and experienced team of scientists, researchers, and executives. This expertise allows the company to effectively develop and bring its drug candidates to market. The team's collective knowledge in various therapeutic areas ensures the development of drugs that address unmet medical needs and have high potential for clinical success. Thirdly, Abionyx Pharma SA benefits from robust partnerships and collaborations with leading academic institutions, research organizations, and other pharmaceutical companies. These collaborations provide access to additional resources, expertise, and funding, enhancing the company's research and development capabilities. Lastly, Abionyx Pharma SA has a strong financial position. This financial stability enables the company to invest in research and development, manufacturing capabilities, and marketing efforts, further strengthening its competitive position.
Weaknesses
- Despite its strengths, Abionyx Pharma SA also faces some weaknesses that should be taken into account. One of the weaknesses is the company's relatively small size compared to some of its competitors. This limits its resources and may affect its ability to compete with larger pharmaceutical companies in terms of market share and brand recognition. Another weakness is the time and cost associated with developing new drugs. The pharmaceutical industry requires substantial investments in research, clinical trials, and regulatory approval processes. Delays or failures in these stages can significantly impact Abionyx Pharma SA's ability to bring its drug candidates to market and generate revenue. Additionally, the company heavily relies on the success of its drug candidates. If any of its major drug candidates fail to meet regulatory requirements or demonstrate efficacy in clinical trials, it could have a negative impact on the company's reputation and financial performance.
Opportunities
- Abionyx Pharma SA operates in an industry with several opportunities for growth and expansion. Firstly, the increasing prevalence of various diseases and medical conditions presents a significant market opportunity for the company. By developing drugs that effectively treat these conditions, Abionyx Pharma SA can tap into a large and growing market. Secondly, advancements in technology and scientific research provide opportunities for the development of innovative therapies and drug delivery systems. Abionyx Pharma SA can leverage these advancements to develop breakthrough treatments that improve patient outcomes and differentiate itself from competitors. Furthermore, the global pharmaceutical market is continuously expanding, especially in emerging economies. Abionyx Pharma SA can explore partnerships and collaborations in these markets to increase its market presence and global reach.
Threats
- Abionyx Pharma SA operates in a highly competitive industry, which presents several threats to its success. Firstly, the presence of major pharmaceutical companies with extensive resources and established market positions poses a challenge to Abionyx Pharma SA's market penetration and growth. Secondly, the regulatory environment and stringent approval processes can be time-consuming and costly. Changes in regulations or delays in obtaining approvals may hinder the company's ability to bring its drugs to market in a timely manner. Additionally, the pharmaceutical industry is subject to constant technological advancements and evolving scientific understanding. If Abionyx Pharma SA fails to keep up with these advancements or fails to anticipate shifts in market demands, it may lose its competitive edge and market share.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.